Quest Diagnostics Inc (DGX) insider trading

Recent insider transactions reported to the SEC on Form 4 — directors and officers buying or selling their own company’s stock. Sourced directly from public SEC filings, latest filed Oct 2, 2026.

Get alerted when insiders buy the stocks you own

Add your holdings — no brokerage login — and Insider Radar sends a Telegram alert when an open-market Form 4 buy of $100,000 or more is filed on a stock you hold or watch.

Free for everyone right now · no card · nothing to buy

Start free
Filings shown
12
Open-market buys
0
Open-market sells
5

Counts cover the 12 most recent Form 4 filings Tradune holds for DGX (filed Jul 27 – Oct 2, 2026). No completed check of DGX's Form 4 list on SEC EDGAR is on record yet; the latest DGX filing Tradune holds was filed Oct 2, 2026. This is not guaranteed to be the complete record — see DGX's full Form 4 filing history on SEC EDGAR.

Open-market activity, last 90 days

Purchases (Form 4 code P) and sales (code S) on the 12 filings Tradune holds for DGX filed Jul 27 – Oct 2, 2026. Grants, exercises, tax withholding and the other Form 4 transaction codes are left out.

5 open-market sales by Rule 10b5-1 checkbox

On filings with the 10b5-1 box checked
5 sales· 34,277 sh
checkbox disclosed
On filings with the box not checked
0 sales· 0 sh
not proof that no plan exists
Not comparable
0 sales· 0 sh
filed before Apr 1, 2023, or no checkbox value in the filing data

Counts are Form 4 lines as filed. The checkbox is one per filing, so every sale on a filing with the box checked is counted there even if only some of its transactions were under a plan; it records what the filer disclosed, and the three categories are not a judgement about why a sale was made.

Open-market purchases and sales by insider
Insider Buys Sells Shares bought Shares sold Value
Michael E. PrevoznikSVP & General Counsel 0 3 — 22,677 −$5,513,083
J. E. DavisCEO and President 0 1 — 10,000 −$2,427,200
Mark E. DelaneySVP & Chief Commercial Officer 0 1 — 1,600 −$376,288

Value = shares × the price reported on each Form 4 (+ purchases, − sales); every open-market line in this window disclosed a price.

Insider-activity score
0/ 100
Net insider sales
0 distinct buyers0 buy · 5 sell tx

Summarises ~90 days of public SEC Form 4 activity — more distinct buyers, officer involvement and net buying score higher. A description of filing activity, not a rating or buy signal. How this score is computed →

How to read this: an open-market purchase (Form 4 code P) is a buy at the market price with the insider’s own money, as opposed to a grant, award or option exercise; an open-market sale is code S. When two or more distinct insiders report open-market purchases in the same 90-day window, this site labels that a cluster — a definition, not a forecast; see insider cluster buying. “Held after” is Form 4 Table I column 5; “Change” = shares ÷ holdings before the trade (held after − shares for an acquisition, held after + shares for a disposition).

Insider Buying at DGX

No open-market insider purchases (Form 4 code P) were reported for DGX in the trailing 90 days. The filings below may include other transaction types — sales, grants, option exercises, and tax withholding — shown for completeness; they are not open-market purchases.

Recent Form 4 filings

Source: SEC EDGAR Form 4 · transaction codes explained

Timothy C. Wentworth Director · filed Oct 2, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award Phantom Stock Units 135 — — — Oct 1, 2026
J. E. Davis CEO and President · filed Sep 3, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box checked 10,000 $242.72 122,423 −7.6% Sep 1, 2026

† change in this filer’s own reported holding line (Form 4 Table I, col. 5), not of total company ownership; small prior holdings produce large percentages, so under 100 shares the prior holding is shown instead.

“10b5-1 box checked” = the filer checked the Form 4 box stating that a transaction on the filing was made under a plan intended to satisfy Rule 10b5-1(c); “10b5-1 box not checked” = the box was left blank, which does not prove that no plan exists. The box applies to Form 4s filed from April 1, 2023; older filings, and boxes we could not read, carry no tag. What the 10b5-1 box means.

Michael E. Prevoznik SVP & General Counsel · filed Aug 31, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box checked 16,010 $242.88 44,224 −27% Aug 28, 2026
Open-market sale 10b5-1 box checked 6,237 $243.63 37,987 −14% Aug 28, 2026
Open-market sale 10b5-1 box checked 430 $244.51 37,557 −1.1% Aug 28, 2026
Gift 1,000 — 36,557 −2.7% Aug 28, 2026
Option exercise Non-Qualifed Stock Option (right to buy) 22,677 $112.17 — — Aug 28, 2026
Option exercise 22,677 $112.17 60,234 +60% Aug 28, 2026
Mark E. Delaney SVP & Chief Commercial Officer · filed Jul 29, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box checked 1,600 $235.18 10,335 −13% Jul 28, 2026
Karthik Kuppusamy SVP, Clinical Solutions · filed Jul 27, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Small acquisition (Rule 16a-6) 37 $206.81 13,557 +0.3% Jul 22, 2026
Robert B. Carter Director · filed Jul 27, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Small acquisition (Rule 16a-6) 11 $206.80 3,864 +0.3% Jul 22, 2026
Vicky B. Gregg Director · filed Jul 27, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award 72 $206.81 18,386 +0.4% Jul 22, 2026
Patrick Plewman SVP for Diagnostic Services · filed Jul 27, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Small acquisition (Rule 16a-6) 46 $206.81 15,293 +0.3% Jul 22, 2026
Timothy L. Main Director · filed Jul 27, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Small acquisition (Rule 16a-6) 21 $206.81 22,460 +0.1% Jul 22, 2026
Sam Samad Executive Vice President & CFO · filed Jul 27, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award 102 $206.81 33,478 +0.3% Jul 22, 2026
Wright Lassiter III Director · filed Jul 27, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Small acquisition (Rule 16a-6) 6 $206.81 10,323 +0.1% Jul 22, 2026
Mark E. Delaney SVP & Chief Commercial Officer · filed Jul 27, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Small acquisition (Rule 16a-6) 34 $206.81 11,935 +0.3% Jul 22, 2026

Insider filings reported around the same time

Other companies whose most recent Form 4 was filed closest to DGX's (Oct 2, 2026).

Frequently asked about DGX insider activity

How many insiders bought DGX stock in the last 90 days?

No open-market purchases (Form 4 code P) of DGX shares were reported by Quest Diagnostics Inc insiders in the trailing 90 days. The 12 filings shown on this page cover other transaction types — sales, grants, option exercises, and tax withholding.

Who filed the most recent Form 4 for DGX?

The most recent Form 4 on this page was filed by Timothy C. Wentworth (Director) on Oct 2, 2026, reporting 1 transaction. The original document is linked from the filing list above on SEC EDGAR. Amended filings (Form 4/A) may later revise reported figures.

What was the largest open-market DGX insider sale shown?

The largest open-market sale among the filings shown was 16,010 DGX shares at $242.88 (about $3,888,437) by Michael E. Prevoznik (SVP & General Counsel) on Aug 28, 2026. Value is shares × the price reported on the Form 4; that Form 4 has the Rule 10b5-1 box checked.

New to Form 4s? The transaction codes, the 90-day window and the 0–100 score are defined on the insider-activity score methodology page.

Get insider alerts for DGX — and your whole portfolio

Tradune watches SEC Form 4 filings and flags insider-cluster buying across everything you hold, routed to you automatically. Free for everyone right now · no card · nothing to buy

Track DGX insider filings free →

This score summarizes SEC Form 4 filing activity over the trailing 90 days. It is descriptive, not predictive — not a rating, recommendation, or investment advice. Data: SEC EDGAR (public domain), as filed; amendments may revise figures. Tradune is not a registered investment adviser.

Data as filed; amended filings (Form 4/A) may revise figures. Sales may occur under prearranged Rule 10b5-1 trading plans.